An antisense strategy to specifically target one of the mutations responsible for FOP

Canadian researchers have developed antisense oligonucleotides (DNA/RNA gapmers) designed to selectively target the R206H mutation in the ACVR1 gene – which is most commonly responsible for progressive ossifying fibrodysplasia (FOP) – whilst sparing the wild-type allele.

  • When evaluated in vitro, the gapmers were effective at preferentially degrading mRNAs from the mutated ACVR1 gene, thereby reducing its expression and abnormal osteogenic differentiation.
  • In wild-type mice, they were distributed throughout the target tissues (skeletal muscles and tendons), whilst limiting toxic accumulation in the kidneys or liver.

These results provide initial proof of concept and will need to be supplemented by further studiesdes qui évalueront l’efficacité thérapeutique et l’innocuité de cette stratégie à long terme.